Urine Proteome in Distinguishing Hepatic Steatosis in Patients with Metabolic-Associated Fatty Liver Disease

Background: In patients with metabolic-associated fatty liver disease (MAFLD), hepatic steatosis is the first step of diagnosis, and it is a risk predictor that independently predicts insulin resistance, cardiovascular risk, and mortality. Urine biomarkers have the advantage of being less complex, w...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Chang-Hai, Zheng, Shanshan, Wang, Shisheng, Wu, Dongbo, Jiang, Wei, Zeng, Qingmin, Wei, Yi, Zhang, Yong, Tang, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9222194/
https://www.ncbi.nlm.nih.gov/pubmed/35741222
http://dx.doi.org/10.3390/diagnostics12061412

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9222194/
https://www.ncbi.nlm.nih.gov/pubmed/35741222
http://dx.doi.org/10.3390/diagnostics12061412

Ejemplares similares